The combination of dabrafenib/trametinib has recently been investigated in cancers with BRAF V600E mutations, such as anaplastic thyroid cancer, melanoma, non-small cell lung cancer, and cholangiocarcinoma, and has shown promise in treating these malignancies. The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.